Imagenetix Announces Issuance of New U.S. Patent for the Prevention and Treatment of Periodontal Disease

Imagenetix Announces Issuance of New U.S. Patent for the Prevention and
Treatment of Periodontal Disease

SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin
Board: IAGX), announced today the issuance of a new U.S. patent (No.
7,612,111). The patent provides intellectual property protection for
Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment
of periodontal disease.

Commenting on the patent issuance, Mr. William P. Spencer, President of
Imagenetix, said, "The issuance is a significant development relating to our
novel technology in the therapeutic treatment of periodontal disease and other
inflammatory related conditions. Imagenetix now owns a broader range of
intellectual property protection on our novel technology with the issuance of
this U.S. patent. Through the guidance of Imagenetix's scientists and
consultants, who are experts in achieving drug approval in this field, we
continue to move forward with our promising drug therapy for the treatment of
periodontitis."

Imagenetix's early stage drug candidate (1-TDC) has been studied at Boston
University's Department of Periodontology and Oral Biology for the treatment
of periodontal disease. In studies published in the Journal of Periodontology,
1-TDC was shown to stop the progression of periodontal disease in a rabbit
periodontitis model. Studies at Boston University also demonstrated
significant improvement and restoration in tissue and bone health compared to
the placebo group.

About Imagenetix
Imagenetix, based in San Diego, California, is an innovator of scientifically
tested, natural-based, proprietary, bioceutical products developed to enhance
human health on a global basis. Imagenetix develops and formulates
proprietary over-the-counter topical creams, skincare products and nutritional
supplements to be marketed globally through multiple channels of distribution.
In addition, the company develops patentable compounds for entering into
licensing agreements with pharmaceutical partners. Please visit,
www.celadrin.com, www.bioguardhealth.com or www.imagenetix.net.

Certain matters in this news release are forward-looking statements which are
subject to risks and uncertainties that could cause actual results to vary
materially from those projected. Such risks and uncertainties include, but
are not limited to, adverse fluctuations in future operating results due to a
number of economic, competitive, and other factors, including, among other
things, the size and timing of customer contracts, new or increased
competition, changes in market demand, and seasonality of purchases of the
company's products and services. Additional information with respect to these
and other factors, which could materially affect the company and its
operations, are included in the company's SEC filings, including its Form 10-K
for the year ended March 31, 2009.

Contact Imagenetix Investor Relations William P. Spencer
(858)385-2797 Chief Executive Officer
Imagenetix, Inc.
Tel: (858) 674-8455

SOURCE Imagenetix, Inc.

Imagenetix Investor Relations, +1-858-385-2797, or William P. Spencer, Chief
Executive Officer of Imagenetix, Inc., +1-858-674-8455